期刊文献+

头孢曲松钠舒巴坦钠(2:1)治疗无合并症淋病的临床疗效及耐药性研究 被引量:4

Clinical efficacy and resistance of ceftriaxone sodium and sulbactam sodium (2:1) in the treatment of uncomplicated gonorrhea
原文传递
导出
摘要 目的评价注射用头孢曲松钠舒巴坦钠(2:1)治疗无合并症淋病的临床疗效、安全性及菌株耐药性。方法采用单臂、多中心、开放性实验设计,在全国7家单位给予入组的113例无合并症淋病受试者单次静脉滴注头孢曲松舒巴坦钠(2:1)3g,监测不良反应,采用治疗后(7±1)d的细菌学清除率评价临床疗效。采用纸片法(K-B法)进行菌株药敏试验,并对产β-内酰胺酶的淋球菌(PPNG)菌株进行头抱菌素类药物的最低抑菌浓度(MIC)分析。结果在97例完成疗效评价的患者中,细菌学清除率达到99.0%。108例完成安全性分析的患者中不良反应发生率4.6%,未发生严重不良事件。100株临床分离的淋球菌菌株经药敏分析,未发现头孢曲松和头孢曲松舒巴坦钠(2:1)中介或耐药。18株PPNG菌株中发现1株头孢曲松钠低敏株,MIC为0.128μ/mL,未检出耐药菌株。结论注射用头孢曲松钠舒巴坦钠(2:1)治疗无合并症淋病临床疗效明确,细菌清除率高,安全性较好,药物敏感性高。 Objective To evaluate the clinical efficacy,safety and drug resistance of ceftriaxone sodium and sulbactam sodium for injection (2:1) in the treatment of uncomplicated gonorrhea.Methods It was a single arm, multi-center and open experiment designed study in 7 centers nationwide.A total of 113 subjects were given ceftriaxone sodium and sulbactam sodium (2:1) 3 g for single intravenous infusion.Adverse reactions were monitored, and the bacterial clearance rate in (7±1) days after treatment was used to evaluate the clinical efficacy.The drug susceptibility was detected by Kirby-Bauer method.The minimum inhibitory concentration (MIC) of cephalosporins against the strains of penicillinase-producing Neisseria gonorrhoeae (PPNG) was analyzed.Results A total of 97 subjects were defined as effective analysis cases,and the bacterial clearance rate was 99.0%.No serious adverse events occurred and the incidence of adverse reactions was 4.6% among 108 cases who completed the drug safety analysis.No intermediate or resistant to ceftriaxone sodium and sulbactam sodium (2:1) strain was found among 100 strains isolated from these patients.One out of 18 PPNG strains was low-sensitive to ceftriaxone sodium with the MIC of 0.128 ug/mL.No drug-resistant strain was detected.Conclusions Ceftriaxone sodium sulbactam sodium for injection (2:1) shows effective clinical efficacy,high bacterial clearance rate,good safety and high drug sensitivity for the treatment of uncomplicated gonorrhea.
作者 石梅 钱伊弘 童炎岳 汪五清 王平 程波 朱莲花 徐顺明 周平玉 Shi Mei;Qian Yihong;Tong Yanyue;Wang Wlining;Wang Ping;Cheng Bo;Zhu Lianhua;Xu Shimming;ZhouPingyu(Department of STD,Shanghai Skin Disease Hospital,Shanghai 200050,China;Department of Urology,People's Hospital of Quzhou,Quzhou 324000,Zhejiang,China;Department of Dermatology,Central Hospital of Minhang District,Shanghai 201199,China;Department of Dermatology,the Third People's Hospital of Hangzhou,Hangzhou 310009,China;Department of Dermatology,the First Affiliated Hospital of Fujian Medical University,Fuzhou 350005,China;Department of Dermatology,Yanbian University Hospital,Yanji 133000,Jilin,China;Departmentof Dermatology,Shanghai Pudong New Area People's Hospital,Shanghai 201299,China)
出处 《国际流行病学传染病学杂志》 CAS 2019年第4期291-295,共5页 International Journal of Epidemiology and Infectious Disease
关键词 淋病 头孢曲松 舒巴坦 细菌清除 不良反应 Gononhea Ceftriaxone Sulbactam Bacterial clearance Adverse reaction
  • 相关文献

参考文献4

二级参考文献26

  • 1白涓涓,王晓娟,顾宜,王荣.头孢曲松钠-舒巴坦钠注射液的人体药动学[J].中国新药杂志,2006,15(9):732-736. 被引量:6
  • 2孙明杰,吕华冲,王霆.注射用哌拉西林钠/舒巴坦钠(2∶1)[J].中国新药杂志,2007,16(13):1061-1064. 被引量:34
  • 3梁建宁,黄莉.HPLC测定注射用头孢曲松钠舒巴坦钠的含量[J].华西药学杂志,2007,22(1):83-84. 被引量:5
  • 4PERAZ F,ENDIMIANI A,HUJER K,et al,The continuing chal- lenge of ESBLs[ J ]. Curt Opin Pharmaco1,2007,7 ( 5 ) :459 - 469.
  • 5BABIC M,HUJER AM,BONOMO R. What's news in antibiotic resis ance? Focus on beta-lactamases [ J ]. Drug Resist Updat. 2006,9(3) :142 - 156.
  • 6BUYNAK JD. Understanding the longevity of the beta-lactam antibiotics and of antibiotic/beta-lactamase inhibitor combination [ J ]. Biochem Pharmacol,2006,71 ( 7 ) :930 - 940.
  • 7国家药品食品监督管理局.β-内酰胺酶抑制剂抗生素复方制剂技术评价原则[EB/OL].(2006-02-06).http://www.sfda. gov. cn/WSOI/CL0055/10498, html.
  • 8罗晓波,成红俊,袁湘敏.非科学性药物制剂的药理学分析[J].中国药业,2007,16(18):21-22. 被引量:1
  • 9刘全忠,王千秋.性传播疾病[M].北京:人民卫生出版社,2011.
  • 10Workowski KA,Berman S,Centers for Disease Control and Prevention (CDC).Sexually transmitted diseases treatment guidelines,2010[J].MMWR Recomm Rep,2010,59(RR-12):1-110.

共引文献306

同被引文献53

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部